(Q61641083)

12

object named as

Marjorie Robert-Guroff

0 references

Barbara Ensoli

11

object named as

Barbara Ensoli

0 references

author name string

Jun Zhao

1

0 references

Rebecca Voltan

2

0 references

Bo Peng

3

0 references

Alberta Davis-Warren

4

0 references

V.S. Kalyanaraman

5

0 references

W. Gregory Alvord

6

0 references

Kris Aldrich

7

0 references

Daniela Bernasconi

8

0 references

Stefano Buttò

9

0 references

Aurelio Cafaro

10

0 references

V S Kalyanaraman

5

0 references

W Gregory Alvord

Quantifying the uncertainty in forecasts of anthropogenic climate change

6

0 references

language of work or name

English

0 references

publication date

November 2005

0 references

10 November 2005

0 references

published in

Virology

0 references

volume

342

0 references

issue

1

0 references

page(s)

1-12

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Recent advances in the development of HIV-1 Tat-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Regulation of Cellular Gene Expression and Function by the Human Immunodeficiency Virus Type 1 Tat Protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

The expression of Fas Ligand by macrophages and its upregulation by human immunodeficiency virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

HIV-1 Tat protein as a potential AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

7 January 2021

The HIV-1 vaccine race

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

The cationic region from HIV tat enhances the cell-surface expression of epitope/MHC class I complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Prospects for vaccine protection against HIV-1 infection and AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Cell-penetrating peptides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

A call for replicating vector prime-protein boost strategies in HIV vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Cellular immune responses to HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Tat-mediated protein delivery can facilitate MHC class I presentation of antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Vaccination with Rev and Tat against AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

HIV regulatory and accessory proteins: new targets for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Tat-neutralizing antibodies in vaccinated macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Evaluation in Rhesus Macaques of Tat and Rev-Targeted Immunization as a Preventive Vaccine against Mucosal Challenge with SHIV-BX08

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Decreased ability of HIV-1 tat protein-treated accessory cells to organize cellular clusters is associated with partial activation of T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016

inferred from DOI database lookup

7 January 2021

based on heuristic

Evaluation of adenovirus type 4 and type 7 recombinant hepatitis B vaccines in dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.07.016